Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Xbrane Biopharma AB ( (SE:XBRANE) ) has provided an update.
Xbrane Biopharma AB announced a reverse share split at a 1:125 ratio, consolidating 125 existing shares into one new share. This move, effective from 17 October 2025, will change the ISIN code for Xbrane’s shares and adjust the total number of shares to 20,605,348. The reverse split aims to streamline the company’s share structure, with no action required from shareholders as the process will be handled automatically. Any excess shares will be sold by Eminova Fondkommission AB, with proceeds distributed to shareholders.
The most recent analyst rating on (SE:XBRANE) stock is a Hold with a SEK0.50 price target. To see the full list of analyst forecasts on Xbrane Biopharma AB stock, see the SE:XBRANE Stock Forecast page.
More about Xbrane Biopharma AB
Xbrane Biopharma AB develops biological drugs using a patented platform technology that reduces production costs significantly compared to competitors. The company has a portfolio of biosimilar candidates targeting an estimated EUR 23 billion in annual peak sales of their reference products. Xbrane’s lead candidate, Ximluci®, received market authorization in Europe and was launched in 2023. The company is headquartered in Solna, Sweden, and is listed on Nasdaq Stockholm.
Average Trading Volume: 13,836,429
Technical Sentiment Signal: Sell
Current Market Cap: SEK676.4M
See more insights into XBRANE stock on TipRanks’ Stock Analysis page.